X4 Pharmaceuticals, Inc 8-K

What Happened

• X4 Pharmaceuticals (XFOR) filed an 8-K on July 1, 2026 announcing that Kelly Gold was appointed as a Class II director, effective July 1, 2026. The Board was expanded from five to six directors and Ms. Gold was also named to the Audit Committee.
• Ms. Gold (age 49) is currently Chief Financial Officer of CAMP4 Therapeutics (since April 2022). Her prior roles include Chief Business Officer and finance/corporate development positions at CAMP4 (2017–2022), Associate Director, Strategic Corporate Finance at Biogen (2014–2017), and healthcare investment banking at Deutsche Bank (2009–2013). She holds bachelor’s degrees in Life Sciences and Mechanical Engineering from Queen’s University and an MBA from MIT Sloan.

Key Details

• Effective date of appointment: July 1, 2026.
• Board size increased from 5 to 6 directors.
• Committee assignment: Audit Committee member.
• Compensation and protections: Ms. Gold will receive standard non-employee director compensation per the company policy and will enter the company’s standard indemnification agreement.
• Independence/related-party: Company reported no arrangements, family relationships, or transactions requiring Item 404 disclosure related to Ms. Gold.

Why It Matters

• The appointment brings additional financial and biopharma experience to X4’s board and strengthens audit oversight by adding a finance-focused director to the Audit Committee.
• Expanding the board may affect governance dynamics and committee composition; investors can view this as a governance enhancement but should note that no specific cash or equity grant details were disclosed beyond the company’s standard director compensation policy.
• This is a governance/board change disclosure (8-K Item 5.02); there are no reported related-party transactions or departures tied to this filing.